Analysis of the Strong Performance of Jinhao Medical (920925) on January 5, 2026

Jinhao Medical (920925)’s strong performance on January 5, 2026 was driven by two factors:

1. Concept and sector linkage
   : The company and another popular BSE stock Beiyikang (920199) both belong to the brain-computer interface (BCI) concept. On that day, this concept became a market favorite, driving collective strength among stocks in the sector [0].
2. Overall sentiment of the BSE
   : On that day, the Beijing Stock Exchange 50 Index rose by 1.80%, market sentiment was high, and 8 BSE stocks made it to the Dragon and Tiger List. Jinhao Medical was selected due to meeting the increase threshold [1].

In terms of technical indicators: The closing price was 38.23 yuan, with an increase of 20.03%; the intraday highest price was 39.75 yuan (an increase of 24.8%) [2]; the trading volume was 10.8265 million shares, with a turnover rate of 19.58%, and the transaction volume was approximately 414 million yuan [1]; Dragon and Tiger List data showed a buying amount of 51.5093 million yuan, a selling amount of 68.0984 million yuan, and a net selling of 16.5892 million yuan, reflecting that some funds had a profit-taking demand [1].

Fundamental support comes from its leading position in domestic hearing aids, benefiting from the demand in the home medical device market brought by the growth of China’s aging population [0].

1. BSE market sentiment transmission
   : Jinhao Medical’s strength is closely linked to the rise of the Beijing Stock Exchange 50 Index and the linkage of stocks within the sector, reflecting the current sentiment-driven characteristics of the BSE market.
2. Short-term nature of concept hype
   : The hype around the brain-computer interface concept lacks clear business progress support. It is necessary to pay attention to the implementation of the company’s related technology layout to judge the sustainability of the market trend.

• Risk points
  :
  • High valuation risk: The dynamic price-earnings ratio reaches 166.5 times, far higher than the industry average, with greater valuation pressure [2];
  • Concept hype risk: The popularity of the brain-computer interface concept may be short-term. If there is no substantive business support, the market trend is prone to a pullback;
  • Profit-taking risk: The net selling on the Dragon and Tiger List and high turnover rate indicate that some funds have started to take profits, and the volatility of subsequent trends may increase.
• Opportunities
  : As a leading domestic hearing aid company, it will benefit from the stable growth of the aging market in the long term, but its short-term performance depends more on market sentiment and concept popularity.

Jinhao Medical (920925)’s strong performance on January 5, 2026 was driven by the hype around the brain-computer interface concept and the overall strength of the BSE market. Technical indicators show high turnover rate and net selling, while fundamentals rely on demand from the aging market. Investors need to pay attention to valuation pressure, concept sustainability, and profit-taking risks, and comprehensively judge subsequent trends based on the company’s business progress and market sentiment.